Metabotropic glutamate receptor 5 : a therapeutic target in Fragile X and a regulator of plasticity in visual cortex

Thesis: Ph. D., Massachusetts Institute of Technology, Department of Brain and Cognitive Sciences, 2014.

Bibliographic Details
Main Author: Sidorov, Michael S. (Michael Samuel)
Other Authors: Mark F. Bear.
Format: Thesis
Language:eng
Published: Massachusetts Institute of Technology 2014
Subjects:
Online Access:http://hdl.handle.net/1721.1/90144
_version_ 1826206781998628864
author Sidorov, Michael S. (Michael Samuel)
author2 Mark F. Bear.
author_facet Mark F. Bear.
Sidorov, Michael S. (Michael Samuel)
author_sort Sidorov, Michael S. (Michael Samuel)
collection MIT
description Thesis: Ph. D., Massachusetts Institute of Technology, Department of Brain and Cognitive Sciences, 2014.
first_indexed 2024-09-23T13:38:16Z
format Thesis
id mit-1721.1/90144
institution Massachusetts Institute of Technology
language eng
last_indexed 2024-09-23T13:38:16Z
publishDate 2014
publisher Massachusetts Institute of Technology
record_format dspace
spelling mit-1721.1/901442019-04-11T10:48:39Z Metabotropic glutamate receptor 5 : a therapeutic target in Fragile X and a regulator of plasticity in visual cortex Therapeutic target in Fragile X and a regulator of plasticity in visual cortex Sidorov, Michael S. (Michael Samuel) Mark F. Bear. Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences. Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences. Brain and Cognitive Sciences. Thesis: Ph. D., Massachusetts Institute of Technology, Department of Brain and Cognitive Sciences, 2014. Cataloged from PDF version of thesis. Vita. Includes bibliographical references (pages 160-185). The synaptic proteins Fragile X mental retardation protein (FMRP) and metabotropic glutamate receptor 5 (mGluR5) act in functional opposition to regulate local translation of synaptic mRNAs. Fragile X is the most common form of inherited intellectual disability and autism, and is expressed by a loss of FMRP. Previous studies have implicated mGluR5 in the pathogenesis of the disease, but a crucial unanswered question is if pharmacological mGluR5 inhibition is able to reverse an already established FX phenotype. Here we use the novel, potent and selective mGluR5 inhibitor CTEP to address this issue. Chronic treatment beginning in young adulthood results in comprehensive phenotype correction, suggesting that FX is in part a disease of acutely altered synapses. These results hold promise for clinical trials currently underway using similar approaches. Identifying mouse phenotypes to model cognitive impairment is especially important in FX because intellectual disability is at the core of the disorder. Here, we describe instrumental extinction as an assay for testing cognitive function, and report that this process is altered in FX model mice. In parallel, we characterize the role of mGluR5 in regulating synaptic and experience-dependent plasticity in wild-type mouse visual cortex. We report that NMDA receptor-dependent long-term depression (LTD) is reduced specifically in layer IV of visual cortex in mGluR5 knockout mice, as well as in wild-type mice treated chronically with CTEP. However, LTD induction is normal in the presence of acute mGIuR5 antagonism in wild-type mice, suggesting an important difference between acute and chronic mGluR5 function. In vivo, monocular deprivation results in experience-driven weakening of synaptic strength, which occurs through similar mechanisms as LTD in vitro. We report that this ocular dominance plasticity is impaired following chronic mGluR5 inhibition. This study shows that specifically in layer IV, chronic but not acute downregulation of mGIuR5 signaling has important consequences for forms of NMDA receptor-dependent plasticity in vitro and in vivo. Taken together, this work addresses both the basic function of mGluR5 as a regulator of plasticity and its potential as a therapeutic target in Fragile X. by Michael S. Sidorov. Ph. D. 2014-09-19T21:42:20Z 2014-09-19T21:42:20Z 2014 2014 Thesis http://hdl.handle.net/1721.1/90144 890197075 eng M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission. http://dspace.mit.edu/handle/1721.1/7582 185 pages application/pdf Massachusetts Institute of Technology
spellingShingle Brain and Cognitive Sciences.
Sidorov, Michael S. (Michael Samuel)
Metabotropic glutamate receptor 5 : a therapeutic target in Fragile X and a regulator of plasticity in visual cortex
title Metabotropic glutamate receptor 5 : a therapeutic target in Fragile X and a regulator of plasticity in visual cortex
title_full Metabotropic glutamate receptor 5 : a therapeutic target in Fragile X and a regulator of plasticity in visual cortex
title_fullStr Metabotropic glutamate receptor 5 : a therapeutic target in Fragile X and a regulator of plasticity in visual cortex
title_full_unstemmed Metabotropic glutamate receptor 5 : a therapeutic target in Fragile X and a regulator of plasticity in visual cortex
title_short Metabotropic glutamate receptor 5 : a therapeutic target in Fragile X and a regulator of plasticity in visual cortex
title_sort metabotropic glutamate receptor 5 a therapeutic target in fragile x and a regulator of plasticity in visual cortex
topic Brain and Cognitive Sciences.
url http://hdl.handle.net/1721.1/90144
work_keys_str_mv AT sidorovmichaelsmichaelsamuel metabotropicglutamatereceptor5atherapeutictargetinfragilexandaregulatorofplasticityinvisualcortex
AT sidorovmichaelsmichaelsamuel therapeutictargetinfragilexandaregulatorofplasticityinvisualcortex